Neurology Department, Ain Shams University, Egypt.
Department 0f Health Sciences, University of Genova, Italy.
Mult Scler Relat Disord. 2021 Nov;56:103324. doi: 10.1016/j.msard.2021.103324. Epub 2021 Oct 10.
This study aimed to report the severity of COVID-19 in a cohort of Egyptian patients with multiple sclerosis (MS) with particular attention on the impact of disease modifying drugs (DMDs).
We included 119 MS patients recruited from two centers, Ain-Shams university and Cairo university with confirmed or suspected COVID-19 during the period from May to September 2020 as a part of the MuSC-19 project. Univariate logistic regression was fitted to assess risk factors for severe COVID-19 (at least one outcome among hospitalization, ICU admission and death).
Females were 77%, mean age was 34 years, mean duration of MS was 5.28 years, median EDSS was 3, most of the patients (83%) had RRMS, while 15% and 2% had respectively SPMS and PPMS. Only eleven patients (9% of study population) had a severe outcome and 3 patients (3%) died. Headache was the only symptom significantly associated with the severity of COVID-19 (OR=10.85, P = 0.001). There was no association between any of the DMDs and severe COVID-19 outcome.
This study showed an acceptable safety profile of DMDs in Egyptian MS patients who developed COVID-19, as 91% of the cohort had a favorable outcome. Headache as a symptom associated with severe outcome in Egyptian patients' needs further validation.
本研究旨在报告埃及多发性硬化症（MS）患者 COVID-19 严重程度，特别关注疾病修正药物（DMDs）的影响。
我们纳入了 119 名来自艾因沙姆斯大学和开罗大学的 MS 患者，他们在 2020 年 5 月至 9 月期间被确诊或疑似患有 COVID-19，这是 MuSC-19 项目的一部分。采用单变量逻辑回归评估严重 COVID-19（至少有住院、ICU 入院和死亡之一的结局）的危险因素。
女性占 77%，平均年龄为 34 岁，MS 平均病程为 5.28 年，EDSS 中位数为 3，大多数患者（83%）为 RRMS，15%和 2%分别为 SPMS 和 PPMS。仅有 11 名患者（研究人群的 9%）出现严重结局，3 名患者（3%）死亡。头痛是与 COVID-19 严重程度唯一显著相关的症状（OR=10.85，P=0.001）。任何 DMD 与严重 COVID-19 结局之间均无关联。
本研究显示埃及 MS 患者 COVID-19 发病后 DMDs 的安全性良好，91%的患者结局良好。头痛作为埃及患者严重结局的相关症状需要进一步验证。
